^
Association details:
| Biomarker: | ROR1 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | LYL797 (ROR1-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors
Published date:
05/03/2022
Excerpt:
Additionally, LYL797 demonstrated overall improved survival and expansion in the peripheral blood of ROR1+ tumor-bearing animals, which correlated with improved anti-tumor activity in an established human ROR1+ NSCLC mouse xenograft model.
